Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 57 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
2. Cita con resumen
Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]
3. Cita con resumen
Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [Ref.ID 99499]
4. Cita con resumen
Anónimo. Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:59-66. [Ref.ID 98172]
5. Cita con resumen
Anónimo. Imatinib et leucémie aiguë lymphoblastique chez les enfants. Prescrire 2014;34:650-1. [Ref.ID 98086]
6.
Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [Ref.ID 95460]
7.
Anónimo. Azathioprine et mercaptopurine: lymphomes. Prescrire 2010;30:910. [Ref.ID 89739]
8. Cita con resumen
Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. Drug Saf 2009;32:91-8. [Ref.ID 85478]
9.Tiene citas relacionadas Cita con resumen
Woodcock J, Lesko LJ. Pharmacogenetics - Tailoring treatment for the outliers. N Engl J Med 2009;360:811-3. [Ref.ID 85288]
10. Cita con resumen
Anónimo. TPMT testing before azathioprine therapy?. Drug Ther Bull 2009;47:9-12. [Ref.ID 85020]
11. Cita con resumen
Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J, for the Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34. [Ref.ID 84961]
12. Cita con resumen
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007;41:21-8. [Ref.ID 79026]
13.Tiene citas relacionadas Cita con resumen
Vora A, Mitchell CD, Lennard L, Eden TOB, Kinsey SE, Lilleyman J, Richards SM, for the Medical Research Council/National Cancer Research Network Childhood Leukaemia Working Party. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-48. [Ref.ID 78226]
14.Tiene citas relacionadas Cita con resumen
Stanulla M, Schünemann HJ. Thioguanine versus mercaptopurine in childhood ALL. Lancet 2006;368:1304-6. [Ref.ID 78215]
15.
Vroom F, de Walle HEK, van de Laar MAJF, Brouwers JRBJ, de Jong-van den Berg LTW. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006;29:845-63. [Ref.ID 78187]
16.
Kingsnorth A, O'Reilly D. Acute pancreatitis. BMJ 2006;332:1072-6. [Ref.ID 76942]
17.
Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66. [Ref.ID 75800]
18.Tiene citas relacionadas
Domènech Morral E, Gassull Duro MA. Actividad eritrocitaria de tiopurina meiltransferasa y tratamiento con tiopurinas en la enfermedad inflamatoria intestinal. Med Clin (Barc) 2005;125:293-4. [Ref.ID 74775]
19.Tiene citas relacionadas
Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG. Actividad de la tiopurina metiltransferasa en la enfermedad inflamatoria intestinal. Un estudio en 7.046 pacientes e. Med Clin (Barc) 2005;125:281-5. [Ref.ID 74774]
Seleccionar todas
 
 1 a 20 de 57 siguiente >>